Ripretinib free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206497

CAS#: 1442472-39-0 (free base)

Description: Ripretinib, also known as DCC-2618, is a potent, orally active and selective KIT/PDGFR inhibitor with potential antineoplastic activity. DCC-2618 targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. In May 2020, FDA Approves Qinlock (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Chemical Structure

img
Ripretinib free base
CAS# 1442472-39-0 (free base)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 206497
Name: Ripretinib free base
CAS#: 1442472-39-0 (free base)
Chemical Formula: C24H21BrFN5O2
Exact Mass: 509.09
Molecular Weight: 510.370
Elemental Analysis: C, 56.48; H, 4.15; Br, 15.66; F, 3.72; N, 13.72; O, 6.27

Price and Availability

Size Price Availability Quantity
10mg USD 150 Ready to ship
25mg USD 250 Ready to ship
50mg USD 450 Ready to ship
100mg USD 750 Ready to ship
200mg USD 1250 Ready to ship
500mg USD 2650 Ready to ship
1g USD 3650 Ready to ship
Bulk inquiry

Related CAS #: 1442472-39-0 (free base)   Ripretinib HCl   1225278-16-9 (wrong structure for DCC-2618)    

Synonym: DCC-2618; DCC 2618; DCC2618; DP 2618; DP-2618; DP2618; Ripretinib;

IUPAC/Chemical Name: 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea

InChi Key: CEFJVGZHQAGLHS-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)

SMILES Code: O=C(NC1=CC(C2=CC3=C(C=C(NC)N=C3)N(CC)C2=O)=C(Br)C=C1F)NC4=CC=CC=C4

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Note: Many vendors listed wrong structure with CAS#1225278-16-9

Biological target: Ripretinib (DCC-2618) is a KIT and PDGFRA switch-control inhibitor.
In vitro activity: Based on this safety profile, ripretinib was formulated into a mouse diet to achieve approximate levels of 100 and 25 mg/kg/day in mouse efficacy studies. In the GIST T1 model treated with ripretinib, significant tumor regression was observed at both doses (Figure 3A). At the high dose, 6/10 mice had complete tumor regression, with the remaining 4/10 mice having partial tumor regression during the dosing period. At the low dose, 2/10 mice had complete tumor regression, and 6/10 had partial tumor regression. Tumors exhibited slow regrowth after the end of the dosing period. Survival to study endpoint (day 68) was 100% for ripretinib-treated mice and 25% for vehicle-treated mice (Figure 3B). Body weight changes for ripretinib-treated groups were similar to vehicle (Figure S4D). Reference: Cancer Cell. 2019 May 13;35(5):738-751.e9. https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30201-6
In vivo activity: DCC-2618 and its active metabolite, DP-5439 were found to inhibit 3H-thymidine uptake and thus proliferation in a dose-dependent manner in all MC lines tested, with slightly lower IC50 values obtained in HMC-1.1 cells lacking KIT D816V and ROSAKIT WT cells compared to the KIT D816V-positive cell lines HMC-1.2 and ROSAKIT D816V (Figure 1A and Table 2). In addition, DCC-2618 and DP-5439 were found to inhibit proliferation of ROSAKIT K509I cells with lower IC50 values (DCC-2618, IC50: 34±10 nM) compared to ROSAKIT D816V cells (Figure 1A). Unexpectedly, DCC-2618 and its metabolite also produced growth-inhibition in the multi-resistant MC lines MCPV-1.1, MCPV-1.2, MCPV-1.3 and MCPV-1.4 (Figure 1B and Table 2). Finally, DCC-2618 and DP- 5439 induced dose-dependent inhibition of growth of primary neoplastic bone marrow cells obtained from patients suffering from various forms of SM, including ASM and MCL (Figure 1C, Table 1). Interestingly, the effects of DCC-2618 on primary neoplastic BM cells and the related IC50 values obtained in different SM variants were comparable (Figure 1C, Table 1). Reference: Haematologica. 2018 May; 103(5): 799–809. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927976/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 25.0 49.00

Preparing Stock Solutions

The following data is based on the product molecular weight 510.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 2019 May 13;35(5):738-751.e9. doi: 10.1016/j.ccell.2019.04.006. PMID: 31085175. 2. Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M, Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E, Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018 May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018 Feb 8. PMID: 29439183; PMCID: PMC5927976.
In vitro protocol: 1. Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 2019 May 13;35(5):738-751.e9. doi: 10.1016/j.ccell.2019.04.006. PMID: 31085175. 2. Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M, Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E, Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018 May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018 Feb 8. PMID: 29439183; PMCID: PMC5927976.
In vivo protocol: 1. Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 2019 May 13;35(5):738-751.e9. doi: 10.1016/j.ccell.2019.04.006. PMID: 31085175.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Baird JH, Gotlib J. Clinical Validation of KIT Inhibition in Advanced Systemic
Mastocytosis. Curr Hematol Malig Rep. 2018 Oct;13(5):407-416. doi:
10.1007/s11899-018-0469-3. Review. PubMed PMID: 30155614.


2: Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M,
Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E,
Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P. The
KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of
multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018
May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018 Feb 8. PubMed
PMID: 29439183; PubMed Central PMCID: PMC5927976.


3: BLU-285, DCC-2618 Show Activity against GIST. Cancer Discov. 2017
Feb;7(2):121-122. doi: 10.1158/2159-8290.CD-NB2016-165. Epub 2017 Jan 11. PubMed
PMID: 28077435.